Reem Elfeky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Reem Elfeky has a total of 403 co-authors. Here are the top co-authors by number of shared publications:
Giovanna Lucchini
Infection, Immunity, and Inflammation Department, GOS Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH BRC, London, United Kingdom
3 shared publicationsKanchan Rao
Department of Bone Marrow Transplant, Great Ormond Street Hospital for Children NHS Foundation Trust University College London GOS Institute of Child Health, and NIHR GOSH BRC London UK
3 shared publications- Catharina Schuetz
Department of Pediatrics, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
2 shared publications - Claire Booth
Great Ormond Street Institute of Child Health, University College London, London, United Kingdom
2 shared publications - Giorgio Ottaviano
Department of Paediatrics, Fondazione MBBM University of Milan-Bicocca, Monza, Italy
2 shared publications - Jesmeen Maimaris
GOS) Hospital for Children NHS Foundation Trust, University College London GOS Institute of Child Health, and NIHR GOSH Biomedical Research Centre 1 Infection, Immunity, and Inflammation Department, Great Ormond Street ( , London
2 shared publications
Latest Publications
- Open Access
- 6 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Beyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease
Data on late complications after hematopoietic stem cell transplantation (HSCT) in children with chronic granulomatous disease (CGD) are limited. We retrospectively analyzed 42 pediatric CGD patients who survived >2 years post-HSCT (1994–2020) at Great Ormond Street Hospital. X-linked CGD accounted for 69%. Pre-HSCT comorbidities included lung disease (48%), colitis/fistulizing disease (45%), and liver abscesses (19%). Median HSCT age was 6 years. 10-year overall survival was 95.2%, and event-free survival (events: death, second intervention) was 81%. 13 (33%) cases developed autoimmunity (AI); eight had relapsing or late-onset (>2 years) AI. Organ-specific late effects included lung abnormalities (n = 7), liver dysfunction (n = 7), renal disease (n = 3), and recurrent/new-onset colitis (n = 3). Endocrine sequelae comprised obesity (n = 15), gonadal dysfunction (n = 9), and short stature (n = 7). Skeletal (n = 6), neurological (n = 6), psychological (n = 19), visual (n = 5), and hearing impairments (n = 4) were noted. Late malignancy was reported in two cases. HSCT offers excellent long-term survival in CGD, but significant late effects underscore the need for extended multidisciplinary follow-up.
- 6 February 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (2)
Open AccessBeyond survival: Multisystem long-term outcomes following HSCT in chronic granulomatous disease
Data on late complications after hematopoietic stem cell transplantation (HSCT) in children with chronic granulomatous disease (CGD) are limited. We retrospectively analyzed 42 pediatric CGD patients who survived >2 years post-HSCT (1994–2020) at Great Ormond Street Hospital. X-linked CGD accounted for 69%. Pre-HSCT comorbidities included lung disease (48%), colitis/fistulizing disease (45%), and liver abscesses (19%). Median HSCT age was 6 years. 10-year overall survival was 95.2%, and event-free survival (events: death, second intervention) was 81%. 13 (33%) cases developed autoimmunity (AI); eight had relapsing or late-onset (>2 years) AI. Organ-specific late effects included lung abnormalities (n = 7), liver dysfunction (n = 7), renal disease (n = 3), and recurrent/new-onset colitis (n = 3). Endocrine sequelae comprised obesity (n = 15), gonadal dysfunction (n = 9), and short stature (n = 7). Skeletal (n = 6), neurological (n = 6), psychological (n = 19), visual (n = 5), and hearing impairments (n = 4) were noted. Late malignancy was reported in two cases. HSCT offers excellent long-term survival in CGD, but significant late effects underscore the need for extended multidisciplinary follow-up.
- 3 December 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (3) , e94-e98
Hemophagocytic Lymphohistiocytosis and Infections in Children: An Update
- 3 December 2025
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 45 (3) , e94-e98
Hemophagocytic Lymphohistiocytosis and Infections in Children: An Update
- 17 November 2025
- Published by Wiley in British Journal of Haematology
- Vol. 208 (1) , 83-95
Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub‐Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy
Summary: Safe and effective haematopoietic stem cell transplant (HSCT) programmes require adequately resourced, well‐trained and experienced multidisciplinary teams. Resources need to be at a level which provides flexibility for development, as indications for HSCT expand and new therapeutic approaches move from experimental to standard practice. The Paediatric British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) group established a working party (WP) to survey the current workforce, to examine the evidence for workforce requirements and to produce recommendations for the medical, nursing, data management, HSCT coordination, quality management, pharmacy and allied health professional workforce requirements for the provision of a safe and effective paediatric transplant centre (TC). These complement the Joint Accreditation Committee of the International Society for Cell and Gene Therapy (ISCT)‐Europe & European Society for Blood and Marrow Transplantation (EBMT) (JACIE) guidance. The WP included representation from haematological and immunological backgrounds, and TCs of different sizes and specialty interests with geographical representation within the UK and Republic of Ireland while consultations were held with a breadth of multidisciplinary groups.
- 17 November 2025
- Published by Wiley in British Journal of Haematology
- Vol. 208 (1) , 83-95
Workforce consensus recommendations for paediatric haematopoietic stem cell transplant centres on behalf of the Paediatric Sub‐Committee of the British Society of Blood and Marrow Transplantation and Cellular Therapy
Summary: Safe and effective haematopoietic stem cell transplant (HSCT) programmes require adequately resourced, well‐trained and experienced multidisciplinary teams. Resources need to be at a level which provides flexibility for development, as indications for HSCT expand and new therapeutic approaches move from experimental to standard practice. The Paediatric British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) group established a working party (WP) to survey the current workforce, to examine the evidence for workforce requirements and to produce recommendations for the medical, nursing, data management, HSCT coordination, quality management, pharmacy and allied health professional workforce requirements for the provision of a safe and effective paediatric transplant centre (TC). These complement the Joint Accreditation Committee of the International Society for Cell and Gene Therapy (ISCT)‐Europe & European Society for Blood and Marrow Transplantation (EBMT) (JACIE) guidance. The WP included representation from haematological and immunological backgrounds, and TCs of different sizes and specialty interests with geographical representation within the UK and Republic of Ireland while consultations were held with a breadth of multidisciplinary groups.
- 10 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (103) , eadq1697
Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature
Human recombination-activating gene (RAG) deficiency can manifest with distinct clinical and immunological phenotypes. By applying a multiomics approach to a large group of RAG -mutated patients, we aimed at characterizing the immunopathology associated with each phenotype. Although defective T and B cell development is common to all phenotypes, patients with hypomorphic RAG variants can generate T and B cells with signatures of immune dysregulation and produce autoantibodies to a broad range of self-antigens, including type I interferons. T helper 2 (T H 2) cell skewing and a prominent inflammatory signature characterize Omenn syndrome, whereas more hypomorphic forms of RAG deficiency are associated with a type 1 immune profile both in blood and tissues. We used cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) analysis to define the cell lineage–specific contribution to the immunopathology of the distinct RAG phenotypes. These insights may help improve the diagnosis and clinical management of the various forms of the disease.
- 10 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (103) , eadq1697
Multiomics dissection of human RAG deficiency reveals distinctive patterns of immune dysregulation but a common inflammatory signature
Human recombination-activating gene (RAG) deficiency can manifest with distinct clinical and immunological phenotypes. By applying a multiomics approach to a large group of RAG -mutated patients, we aimed at characterizing the immunopathology associated with each phenotype. Although defective T and B cell development is common to all phenotypes, patients with hypomorphic RAG variants can generate T and B cells with signatures of immune dysregulation and produce autoantibodies to a broad range of self-antigens, including type I interferons. T helper 2 (T H 2) cell skewing and a prominent inflammatory signature characterize Omenn syndrome, whereas more hypomorphic forms of RAG deficiency are associated with a type 1 immune profile both in blood and tissues. We used cellular indexing of transcriptomes and epitopes by sequencing (CITE-seq) analysis to define the cell lineage–specific contribution to the immunopathology of the distinct RAG phenotypes. These insights may help improve the diagnosis and clinical management of the various forms of the disease.
- Open Access
- 15 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5838-5852
Pediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children
Several attempts have been made to optimize pretransplant risk assessment to improve hematopoietic stem cell transplantation (HSCT) decision-making and to predict post-HSCT outcomes. However, the relevance of pretransplant risk assessment to the pediatric population remains unclear. We report the results of revalidation of the hematopoietic cell transplantation comorbidity index (HCT-CI) in 874 children who received 944 HSCTs for malignant or nonmalignant diseases at a single center. After finding the HCT-CI invalid in our patient population, we proposed a modified pediatric adapted scoring system that captures risk factors (RFs) and comorbidities (CoMs) relevant to pediatrics. Each RF/CoM was assigned an integer weight based on its hazard ratio (HR) for transplant-related mortality (TRM): 0 (HR < 1.2), 1 (1.2 ≥ HR < 1.75), 2 (1.75 ≥ HR < 2.5), and 3 (HR ≥ 2.5). Using these weights, the pediatric adapted risk index (PARI) for HSCT was devised, and patients were divided into 4 risk groups (group 1: without RF/CoM; group 2: score 1-2; group 3: score 3-4; and group 4: score ≥5). There was a linear increase in 2-year TRM from group 1 to 4 (TRM, 6.2% in group 1, 50.9% in group 4). PARI was successfully validated on an internal and external cohort of pediatric patients. Comparing models using c-statistics, PARI was found to have better performance than HCT-CI in predicting 2-year TRM in children, with Akaike and Schwarz Bayesian information criteria values of 1069.245 and 1073.269, respectively, using PARI, vs 1223.158 and 1227.051, respectively, using HCT-CI. We believe that PARI will be a valuable tool enabling better counseling and decision-making for pediatric patients with HSCT.
- 15 November 2024
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (22) , 5838-5852
Open AccessPediatric adapted risk index to predict 2-year transplant-related mortality post-HSCT in children
Several attempts have been made to optimize pretransplant risk assessment to improve hematopoietic stem cell transplantation (HSCT) decision-making and to predict post-HSCT outcomes. However, the relevance of pretransplant risk assessment to the pediatric population remains unclear. We report the results of revalidation of the hematopoietic cell transplantation comorbidity index (HCT-CI) in 874 children who received 944 HSCTs for malignant or nonmalignant diseases at a single center. After finding the HCT-CI invalid in our patient population, we proposed a modified pediatric adapted scoring system that captures risk factors (RFs) and comorbidities (CoMs) relevant to pediatrics. Each RF/CoM was assigned an integer weight based on its hazard ratio (HR) for transplant-related mortality (TRM): 0 (HR < 1.2), 1 (1.2 ≥ HR < 1.75), 2 (1.75 ≥ HR < 2.5), and 3 (HR ≥ 2.5). Using these weights, the pediatric adapted risk index (PARI) for HSCT was devised, and patients were divided into 4 risk groups (group 1: without RF/CoM; group 2: score 1-2; group 3: score 3-4; and group 4: score ≥5). There was a linear increase in 2-year TRM from group 1 to 4 (TRM, 6.2% in group 1, 50.9% in group 4). PARI was successfully validated on an internal and external cohort of pediatric patients. Comparing models using c-statistics, PARI was found to have better performance than HCT-CI in predicting 2-year TRM in children, with Akaike and Schwarz Bayesian information criteria values of 1069.245 and 1073.269, respectively, using PARI, vs 1223.158 and 1227.051, respectively, using HCT-CI. We believe that PARI will be a valuable tool enabling better counseling and decision-making for pediatric patients with HSCT.
- Open Access
- 22 December 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (1) , 1-12
Prevalence and Characteristics of Non-tuberculous Mycobacteria (NTM) Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: a Systematic Review and Meta-analysis
Purpose: Non-tuberculous mycobacteria (NTM) infections in hematopoietic stem cell transplantation (HSCT) recipients represent a diagnostic and therapeutic challenge. Here, we aimed to review and analyze current literature on incidence, clinical presentation, and outcome of NTM infection after allogeneic HSCT. Methods: We performed a systematic review and meta-analysis of available literature regarding NTM infection in children and adults receiving allogeneic HSCT. Results: We identified 56 articles eligible for the analysis. Among 15 studies, describing 15,798 allogeneic HSCT, we estimated a prevalence of 1.26% (95% CI 0.72, 1.93) of NTM after transplant. Analysis of 175 patients with NTM infection showed a median time of diagnosis of 318 days after HSCT, an increased prevalence in adults (82.9%), and a most frequent pulmonary involvement (44%). Comparison between children and adults revealed an earlier post-transplant disease onset (median 130 days vs 287 days) and most frequent non-pulmonary presentation in children. A vast heterogeneity of therapeutic approach reflected the lack of universal recommendations regarding drug combination and duration of therapy. Overall, NTM-related mortality accounted for 33% in this systematic review. Conclusion: Although rare, NTM infections can complicate post-transplant course with a high mortality rate in children and adults. The lack of prospective studies and guidelines prevents identification of risk factors and therapeutic recommendations.
- 22 December 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 44 (1) , 1-12
Open AccessPrevalence and Characteristics of Non-tuberculous Mycobacteria (NTM) Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation: a Systematic Review and Meta-analysis
Purpose: Non-tuberculous mycobacteria (NTM) infections in hematopoietic stem cell transplantation (HSCT) recipients represent a diagnostic and therapeutic challenge. Here, we aimed to review and analyze current literature on incidence, clinical presentation, and outcome of NTM infection after allogeneic HSCT. Methods: We performed a systematic review and meta-analysis of available literature regarding NTM infection in children and adults receiving allogeneic HSCT. Results: We identified 56 articles eligible for the analysis. Among 15 studies, describing 15,798 allogeneic HSCT, we estimated a prevalence of 1.26% (95% CI 0.72, 1.93) of NTM after transplant. Analysis of 175 patients with NTM infection showed a median time of diagnosis of 318 days after HSCT, an increased prevalence in adults (82.9%), and a most frequent pulmonary involvement (44%). Comparison between children and adults revealed an earlier post-transplant disease onset (median 130 days vs 287 days) and most frequent non-pulmonary presentation in children. A vast heterogeneity of therapeutic approach reflected the lack of universal recommendations regarding drug combination and duration of therapy. Overall, NTM-related mortality accounted for 33% in this systematic review. Conclusion: Although rare, NTM infections can complicate post-transplant course with a high mortality rate in children and adults. The lack of prospective studies and guidelines prevents identification of risk factors and therapeutic recommendations.
- Top Cited PapersOpen Access
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
The Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- 11 November 2023
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 52 (D1) , D1333-D1346
Top Cited PapersOpen AccessThe Human Phenotype Ontology in 2024: phenotypes around the world
The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
- Open Access
- 26 June 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (7) , 1519-1525
Immunoglobulin Replacement Therapy During COVID-19 Pandemic: Practical and Psychological Impact in Patients with Antibody Deficiency
Purpose: The COVID-19 pandemic has impacted on how health services deliver care and the mental health of the population. Due to their clinical vulnerability, to reduce in-hospital attendances during the COVID-19 pandemic, modifications in immunoglobulin treatment regimens were made for patients with antibody deficiency. These patients were also likely to experience social isolation due to shielding measure that were advised. We aimed to investigate the impact of modifying immunoglobulin treatment regimen on infection and mental health burden during shielding restrictions.Method: Patients on immunoglobulin replacement therapy (IGRT) responded to a standardised questionnaire examining self-reported infection frequency, anxiety (GAD-7), depression (PHQ-8), fatigue (FACIT), and quality of life during the pandemic. Infection frequency and immunoglobulin trough levels were compared to pre-pandemic levels.Results: Patients who did not change treatment modality or those who received immunoglobulin replacement at home during the pandemic reported fewer infections. In patients who received less frequent hospital infusions, there was no significant increase in infections whilst immunoglobulin trough levels remained stable. There was no significant difference in anxiety, or depression scores between the treatment modality groups. Patients reported higher fatigue scores compared to the pre-COVID general population and in those discharged following hospitalisation for COVID.Conclusion: Changing immunoglobulin treatment regimen did not negatively impact infection rates or psychological wellbeing. However, psychological welfare should be prioritised for this group particularly given uncertainties around COVID-19 vaccination responsiveness and continued social isolation for many.
- 26 June 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (7) , 1519-1525
Open AccessImmunoglobulin Replacement Therapy During COVID-19 Pandemic: Practical and Psychological Impact in Patients with Antibody Deficiency
Purpose: The COVID-19 pandemic has impacted on how health services deliver care and the mental health of the population. Due to their clinical vulnerability, to reduce in-hospital attendances during the COVID-19 pandemic, modifications in immunoglobulin treatment regimens were made for patients with antibody deficiency. These patients were also likely to experience social isolation due to shielding measure that were advised. We aimed to investigate the impact of modifying immunoglobulin treatment regimen on infection and mental health burden during shielding restrictions.Method: Patients on immunoglobulin replacement therapy (IGRT) responded to a standardised questionnaire examining self-reported infection frequency, anxiety (GAD-7), depression (PHQ-8), fatigue (FACIT), and quality of life during the pandemic. Infection frequency and immunoglobulin trough levels were compared to pre-pandemic levels.Results: Patients who did not change treatment modality or those who received immunoglobulin replacement at home during the pandemic reported fewer infections. In patients who received less frequent hospital infusions, there was no significant increase in infections whilst immunoglobulin trough levels remained stable. There was no significant difference in anxiety, or depression scores between the treatment modality groups. Patients reported higher fatigue scores compared to the pre-COVID general population and in those discharged following hospitalisation for COVID.Conclusion: Changing immunoglobulin treatment regimen did not negatively impact infection rates or psychological wellbeing. However, psychological welfare should be prioritised for this group particularly given uncertainties around COVID-19 vaccination responsiveness and continued social isolation for many.
- Open Access
- 12 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1186575
Combined novel homozygous variants in both SGPL1 and STAT1 presenting with severe combined immune deficiency: case report and literature review
Background: Sphingosine phosphate lyase insufficiency syndrome (SPLIS) is associated with biallelic variants in SGPL1, comprising a multisystemic disease characterized by steroid resistant nephrotic syndrome, primary adrenal insufficiency, neurological problems, skin abnormalities and immunodeficiency in described cases. Signal transducer and activator of transcription 1 (STAT1) plays an important role in orchestrating an appropriate immune response through JAK-STAT pathway. Biallelic STAT1 loss of function (LOF) variants lead to STAT1 deficiency with a severe phenotype of immunodeficiency with increased frequency of infections and poor outcome if untreated.Case presentation: We report novel homozygous SGPL1 and STAT1 variants in a newborn of Gambian ethnicity with clinical features of SPLIS and severe combined immunodeficiency. The patient presented early in life with nephrotic syndrome, severe respiratory infection requiring ventilation, ichthyosis, and hearing loss, with T-cell lymphopenia. The combination of these two conditions led to severe combined immunodeficiency with inability to clear respiratory tract infections of viral, fungal, and bacterial nature, as well as severe nephrotic syndrome. The child sadly died at 6 weeks of age despite targeted treatments.Conclusion: We report the finding of two novel, homozygous variants in SGPL1 and STAT1 in a patient with a severe clinical phenotype and fatal outcome early in life. This case highlights the importance of completing the primary immunodeficiency genetic panel in full to avoid missing a second diagnosis in other patients presenting with similar severe clinical phenotype early in life. For SPLIS no curative treatment is available and more research is needed to investigate different treatment modalities. Hematopoietic stem cell transplantation (HSCT) shows promising results in patients with autosomal recessive STAT1 deficiency. For this patient’s family, identification of the dual diagnosis has important implications for future family planning. In addition, future siblings with the familial STAT1 variant can be offered curative treatment with HSCT.
- 12 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1186575
Open AccessCombined novel homozygous variants in both SGPL1 and STAT1 presenting with severe combined immune deficiency: case report and literature review
Background: Sphingosine phosphate lyase insufficiency syndrome (SPLIS) is associated with biallelic variants in SGPL1, comprising a multisystemic disease characterized by steroid resistant nephrotic syndrome, primary adrenal insufficiency, neurological problems, skin abnormalities and immunodeficiency in described cases. Signal transducer and activator of transcription 1 (STAT1) plays an important role in orchestrating an appropriate immune response through JAK-STAT pathway. Biallelic STAT1 loss of function (LOF) variants lead to STAT1 deficiency with a severe phenotype of immunodeficiency with increased frequency of infections and poor outcome if untreated.Case presentation: We report novel homozygous SGPL1 and STAT1 variants in a newborn of Gambian ethnicity with clinical features of SPLIS and severe combined immunodeficiency. The patient presented early in life with nephrotic syndrome, severe respiratory infection requiring ventilation, ichthyosis, and hearing loss, with T-cell lymphopenia. The combination of these two conditions led to severe combined immunodeficiency with inability to clear respiratory tract infections of viral, fungal, and bacterial nature, as well as severe nephrotic syndrome. The child sadly died at 6 weeks of age despite targeted treatments.Conclusion: We report the finding of two novel, homozygous variants in SGPL1 and STAT1 in a patient with a severe clinical phenotype and fatal outcome early in life. This case highlights the importance of completing the primary immunodeficiency genetic panel in full to avoid missing a second diagnosis in other patients presenting with similar severe clinical phenotype early in life. For SPLIS no curative treatment is available and more research is needed to investigate different treatment modalities. Hematopoietic stem cell transplantation (HSCT) shows promising results in patients with autosomal recessive STAT1 deficiency. For this patient’s family, identification of the dual diagnosis has important implications for future family planning. In addition, future siblings with the familial STAT1 variant can be offered curative treatment with HSCT.
- Open Access
- 17 March 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (5) , 1019-1031
Non-osteopenic Bone Pathology After Allo-hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity
Purpose: There is a lack of data on post-HSCT non-osteopenic bone pathology specifically for children with inborn errors of immunity (IEI). We collected data on non-osteopenic bone pathology in children with IEI post-HSCT over two decades in a large tertiary pediatric immunology center. Methods: Descriptive study with data analysis of bone pathology in allo-HSCT for IEI was performed between 1/1/2000 to 31/12/2018 including patients alive at follow-up to July 2022. Records were analyzed for bone pathology and risk factors. Exclusion criteria included isolated reduced bone density, fractures, and skeletal anomalies due to underlying IEI and short stature without other bone pathology. Bone pathologies were divided into 5 categories: bone tumors; skeletal dysplasia; avascular necrosis; evolving bone deformities; slipped upper femoral epiphysis. Results: A total of 429 children received HSCT between 2000 and 2018; 340 are alive at last assessment. Non-osteopenic bone pathology was observed post-HSCT in 9.4% of patients (32/340, mean 7.8 years post-HSCT). Eleven patients (34%) had > 1 category of bone pathology. Seventeen patients (17/32; 53%) presented with bilateral bone pathology. The majority of patients received treosulfan-based conditioning (26/32; 81.2%). Totally, 65.6% (21/32) of patients had a history of prolonged steroid use (> 6 months). Pain was the presenting symptom in 66% of patients, and surgical intervention was required in 43.7%. The highest incidence of bone pathologies was seen in Wiskott-Aldrich syndrome (WAS) (n = 8/34; 23.5%) followed by hemophagocytic lymphohistiocytosis patients (n = 3/16; 18.8%). Conclusion: Non-osteopenic bone pathology in long-term survivors of allo-HSCT for IEI is not rare. Most patients did not present with complaints until at least 5 years post-HSCT highlighting the need for ongoing bone health assessment for patients with IEI. Children presenting with stunted growth and bone pathology post-HSCT should undergo skeletal survey to rule out development of post-HSCT skeletal dysplasia. Increased rates and complexity of bone pathology were seen amongst patients with Wiskott-Aldrich syndrome.
- 17 March 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (5) , 1019-1031
Open AccessNon-osteopenic Bone Pathology After Allo-hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity
Purpose: There is a lack of data on post-HSCT non-osteopenic bone pathology specifically for children with inborn errors of immunity (IEI). We collected data on non-osteopenic bone pathology in children with IEI post-HSCT over two decades in a large tertiary pediatric immunology center. Methods: Descriptive study with data analysis of bone pathology in allo-HSCT for IEI was performed between 1/1/2000 to 31/12/2018 including patients alive at follow-up to July 2022. Records were analyzed for bone pathology and risk factors. Exclusion criteria included isolated reduced bone density, fractures, and skeletal anomalies due to underlying IEI and short stature without other bone pathology. Bone pathologies were divided into 5 categories: bone tumors; skeletal dysplasia; avascular necrosis; evolving bone deformities; slipped upper femoral epiphysis. Results: A total of 429 children received HSCT between 2000 and 2018; 340 are alive at last assessment. Non-osteopenic bone pathology was observed post-HSCT in 9.4% of patients (32/340, mean 7.8 years post-HSCT). Eleven patients (34%) had > 1 category of bone pathology. Seventeen patients (17/32; 53%) presented with bilateral bone pathology. The majority of patients received treosulfan-based conditioning (26/32; 81.2%). Totally, 65.6% (21/32) of patients had a history of prolonged steroid use (> 6 months). Pain was the presenting symptom in 66% of patients, and surgical intervention was required in 43.7%. The highest incidence of bone pathologies was seen in Wiskott-Aldrich syndrome (WAS) (n = 8/34; 23.5%) followed by hemophagocytic lymphohistiocytosis patients (n = 3/16; 18.8%). Conclusion: Non-osteopenic bone pathology in long-term survivors of allo-HSCT for IEI is not rare. Most patients did not present with complaints until at least 5 years post-HSCT highlighting the need for ongoing bone health assessment for patients with IEI. Children presenting with stunted growth and bone pathology post-HSCT should undergo skeletal survey to rule out development of post-HSCT skeletal dysplasia. Increased rates and complexity of bone pathology were seen amongst patients with Wiskott-Aldrich syndrome.